This is an outdated version published on 2026-08-01. Read the most recent version.

The Specialized Brain Nutrient Milieu Shapes Tumor Metabolism

Authors

RUOLUN WEI Stanford Medicine

DOI:

Abstract

Brain tumors arise within a uniquely specialized metabolic environment that differs fundamentally from that of peripheral solid tumors. In the normal brain, nutrient access is constrained by the blood–brain barrier, metabolic functions are partitioned across distinct neural cell types, and key substrates such as glucose, lipids, glutamate, lactate, and cholesterol are handled in organ-specific ways. As a result, glioma metabolism is shaped not only by oncogenic signaling, but also by adaptation to the native brain nutrient milieu. In this review, we propose that brain tumors, particularly glioblastoma, are best understood as hijacking and rewiring pre-existing metabolic programs of the brain rather than simply amplifying canonical cancer pathways. We further highlight how this perspective helps explain the distinctive roles of nutrient repartitioning, intercellular metabolic cooperation, and redox adaptation in glioma progression, and why these features may create therapeutically actionable vulnerabilities. Together, this framework supports a shift from broad metabolic inhibition toward targeting brain-adapted metabolic dependencies in glioma.

References

Reference

1. Wu, D. et al. The blood–brain barrier: Structure, regulation and drug delivery. Sig Transduct Target Ther 8, 217 (2023).

2. Bonvento, G. & Bolaños, J. P. Astrocyte-neuron metabolic cooperation shapes brain activity. Cell Metabolism 33, 1546–1564 (2021).

3. Pellerin, L. et al. Evidence supporting the existence of an activity-dependent astrocyte-neuron lactate shuttle. Dev Neurosci 20, 291–299 (1998).

4. Suzuki, A. et al. Astrocyte-Neuron Lactate Transport Is Required for Long-Term Memory Formation. Cell 144, 810–823 (2011).

5. Philips, T. & Rothstein, J. D. Oligodendroglia: metabolic supporters of neurons. J Clin Invest 127, 3271–3280 (2017).

6. Lee, Y. et al. Oligodendroglia metabolically support axons and contribute to neurodegeneration. Nature 487, 443–448 (2012).

7. Hasel, P., Aisenberg, W. H., Bennett, F. C. & Liddelow, S. A. Molecular and metabolic heterogeneity of astrocytes and microglia. Cell Metabolism 35, 555–570 (2023).

8. Shin, K. C., Ali Moussa, H. Y. & Park, Y. Cholesterol imbalance and neurotransmission defects in neurodegeneration. Exp Mol Med 56, 1685–1690 (2024).

9. Mauch, D. H. et al. CNS synaptogenesis promoted by glia-derived cholesterol. Science 294, 1354–1357 (2001).

10. Orth, M. & Bellosta, S. Cholesterol: Its Regulation and Role in Central Nervous System Disorders. Cholesterol 2012, 292598 (2012).

11. Zhang, J. & Liu, Q. Cholesterol metabolism and homeostasis in the brain. protein. cell. 6, 254–264 (2015).

12. Rudajev, V. & Novotny, J. Cholesterol as a key player in amyloid β-mediated toxicity in Alzheimer’s disease. Front Mol Neurosci 15, 937056 (2022).

13. Habchi, J. et al. Cholesterol catalyses Aβ42 aggregation through a heterogeneous nucleation pathway in the presence of lipid membranes. Nat Chem 10, 673–683 (2018).

14. Pfrieger, F. W. & Ungerer, N. Cholesterol metabolism in neurons and astrocytes. Prog Lipid Res 50, 357–371 (2011).

15. Mergenthaler, P., Lindauer, U., Dienel, G. A. & Meisel, A. Sugar for the brain: the role of glucose in physiological and pathological brain function. Trends Neurosci 36, 587–597 (2013).

16. Rae, C. D. et al. Brain energy metabolism: A roadmap for future research. J Neurochem 168, 910–954 (2024).

17. Magistretti, P. J. & Allaman, I. A Cellular Perspective on Brain Energy Metabolism and Functional Imaging. Neuron 86, 883–901 (2015).

18. Bentsen, M. A., Mirzadeh, Z. & Schwartz, M. W. Revisiting how the brain senses glucose - and why. Cell Metab 29, 11–17 (2019).

19. Daneman, R. & Prat, A. The Blood–Brain Barrier. Cold Spring Harb Perspect Biol 7, a020412 (2015).

20. Adeva-Andany, M. M., González-Lucán, M., Donapetry-García, C., Fernández-Fernández, C. & Ameneiros-Rodríguez, E. Glycogen metabolism in humans. BBA Clin 5, 85–100 (2016).

21. Cao, Y., Zhao, L.-W., Chen, Z.-X. & Li, S.-H. New insights in lipid metabolism: potential therapeutic targets for the treatment of Alzheimer’s disease. Front Neurosci 18, 1430465 (2024).

22. Maehashi, S., Arora, K., Fisher, A. L., Schweitzer, D. R. & Akefe, I. O. Neurolipidomic insights into anxiety disorders: Uncovering lipid dynamics for potential therapeutic advances. Neuroscience & Biobehavioral Reviews 163, 105741 (2024).

23. Corraliza-Gomez, M., Sanchez, D. & Ganfornina, M. D. Lipid-Binding Proteins in Brain Health and Disease. Front Neurol 10, 1152 (2019).

24. Montani, L. Lipids in regulating oligodendrocyte structure and function. Seminars in Cell & Developmental Biology 112, 114–122 (2021).

25. Sambra, V., Echeverria, F., Valenzuela, A., Chouinard-Watkins, R. & Valenzuela, R. Docosahexaenoic and Arachidonic Acids as Neuroprotective Nutrients throughout the Life Cycle. Nutrients 13, 986 (2021).

26. Tallima, H. & El Ridi, R. Arachidonic acid: Physiological roles and potential health benefits – A review. Journal of Advanced Research 11, 33–41 (2018).

27. Tanaka, K., Farooqui, A. A., Siddiqi, N. J., Alhomida, A. S. & Ong, W.-Y. Effects of Docosahexaenoic Acid on Neurotransmission. Biomol Ther (Seoul) 20, 152–157 (2012).

28. Meldrum, B. S. Glutamate as a Neurotransmitter in the Brain: Review of Physiology and Pathology. The Journal of Nutrition 130, 1007S-1015S (2000).

29. Shen, J. Modeling the glutamate–glutamine neurotransmitter cycle. Front. Neuroenergetics 5, (2013).

30. Zhou, Y. & Danbolt, N. C. Glutamate as a neurotransmitter in the healthy brain. J Neural Transm 121, 799–817 (2014).

31. Agarwal, N. & Renshaw, P. F. Proton MR Spectroscopy–Detectable Major Neurotransmitters of the Brain: Biology and Possible Clinical Applications. AJNR Am J Neuroradiol 33, 595–602 (2012).

32. Schousboe, A., Scafidi, S., Bak, L. K., Waagepetersen, H. S. & McKenna, M. C. Glutamate Metabolism in the Brain Focusing on Astrocytes. Adv Neurobiol 11, 13–30 (2014).

33. Hohnholt, M. C. et al. Glutamate dehydrogenase is essential to sustain neuronal oxidative energy metabolism during stimulation. J Cereb Blood Flow Metab 38, 1754–1768 (2018).

34. Dienel, G. A. Astrocytic energetics during excitatory neurotransmission: What are contributions of glutamate oxidation and glycolysis? Neurochem Int 63, 244–258 (2013).

35. Schousboe, A., Bak, L. K. & Waagepetersen, H. S. Astrocytic Control of Biosynthesis and Turnover of the Neurotransmitters Glutamate and GABA. Front. Endocrinol. 4, (2013).

36. Barros, L. F. Metabolic signaling by lactate in the brain. Trends in Neurosciences 36, 396–404 (2013).

37. Wu, A., Lee, D. & Xiong, W.-C. Lactate Metabolism, Signaling, and Function in Brain Development, Synaptic Plasticity, Angiogenesis, and Neurodegenerative Diseases. Int J Mol Sci 24, 13398 (2023).

38. Bélanger, M., Allaman, I. & Magistretti, P. J. Brain Energy Metabolism: Focus on Astrocyte-Neuron Metabolic Cooperation. Cell Metabolism 14, 724–738 (2011).

39. Tang, B. L. Brain activity-induced neuronal glucose uptake/glycolysis: Is the lactate shuttle not required? Brain Research Bulletin 137, 225–228 (2018).

40. Mason, S. Lactate Shuttles in Neuroenergetics—Homeostasis, Allostasis and Beyond. Front Neurosci 11, 43 (2017).

41. Scott, A. J. et al. Rewiring of cortical glucose metabolism fuels human brain cancer growth. Nature 646, 413–422 (2025).

42. Scott, A. J. et al. Rewiring of cortical glucose metabolism fuels human brain cancer growth. Nature 646, 413–422 (2025).

43. Zhao, J. et al. Advancing glioblastoma treatment by targeting metabolism. Neoplasia 51, 100985 (2024).

44. Hong, Y., Hua, C. & Wu, M. Repartitioning brain glucose: serine–nucleotide dependency sensitizes glioblastoma therapy. Sig Transduct Target Ther 10, 404 (2025).

45. Bernhard, C., Reita, D., Martin, S., Entz-Werle, N. & Dontenwill, M. Glioblastoma Metabolism: Insights and Therapeutic Strategies. Int J Mol Sci 24, 9137 (2023).

46. Tardito, S. et al. Glutamine synthetase activity fuels nucleotide biosynthesis and supports growth of glutamine-restricted glioblastoma. Nat Cell Biol 17, 1556–1568 (2015).

47. Swain, J. de R., Michalopoulou, E., Noch, E. K., Lukey, M. J. & Aelst, L. V. Metabolic partitioning in the brain and its hijacking by glioblastoma. Genes Dev. 37, 681–702 (2023).

48. Bailleul, J. & Vlashi, E. Glioblastomas: Hijacking Metabolism to Build a Flexible Shield for Therapy Resistance. Antioxid Redox Signal 39, 957–979 (2023).

49. Divé, I. et al. Tumor-associated epilepsy and high expression of xCT shape the proteome of IDH-wildtype glioblastoma. Cell Death Discov. 12, 180 (2026).

50. Divé, I. et al. Tumor-associated epilepsy and high expression of xCT shape the proteome of IDH-wildtype glioblastoma. Cell Death Discov. 12, 180 (2026).

51. Bouwen, B. L. J. et al. Aberrant neural activity in the peritumoral cortex underlies the progression of tumor-associated seizures. Nat Commun 16, 10846 (2025).

52. Rossi, J. et al. Epileptogenesis and Tumorigenesis in Glioblastoma: Which Relationship? Medicina (Kaunas) 58, 1349 (2022).

53. Mason, S. Lactate Shuttles in Neuroenergetics—Homeostasis, Allostasis and Beyond. Front. Neurosci. 11, (2017).

54. Wang, S. et al. Lactate reprograms glioblastoma immunity through CBX3-regulated histone lactylation. J Clin Invest 134, e176851 (2024).

55. Wang, Z. et al. Tumor-secreted lactate contributes to an immunosuppressive microenvironment and affects CD8 T-cell infiltration in glioblastoma. Front Immunol 14, 894853 (2023).

56. Kim, Y., Dube, S. E. & Park, C. B. Brain energy homeostasis: the evolution of the astrocyte-neuron lactate shuttle hypothesis. Korean J Physiol Pharmacol 29, 1–8 (2025).

57. Lee, H., Kim, D. & Youn, B. Targeting Oncogenic Rewiring of Lipid Metabolism for Glioblastoma Treatment. International Journal of Molecular Sciences 23, 13818 (2022).

58. de Ruiter Swain, J., Michalopoulou, E., Noch, E. K., Lukey, M. J. & Van Aelst, L. Metabolic partitioning in the brain and its hijacking by glioblastoma. Genes Dev 37, 681–702 (2023).

59. Kloosterman, D. J. et al. Macrophage-mediated myelin recycling fuels brain cancer malignancy. Cell 187, 5336-5356.e30 (2024).

60. Lee, H., Kim, D. & Youn, B. Targeting Oncogenic Rewiring of Lipid Metabolism for Glioblastoma Treatment. International Journal of Molecular Sciences 23, 13818 (2022).

61. Zhao, W. et al. The proto-oncogene tyrosine kinase c-SRC facilitates glioblastoma progression by remodeling fatty acid synthesis. Nat Commun 15, 7455 (2024).

62. Mashimo, T. et al. Acetate is a Bioenergetic Substrate for Human Glioblastoma and Brain Metastases. Cell 159, 1603–1614 (2014).

63. Rebello, C. J. Polyunsaturated Fatty Acid Intake and Brain Health: Balance is the Key. Am J Geriatr Psychiatry 30, 774–776 (2022).

64. Liu, Z., Ma, Z., Yang, K. & Fan, H. Ferroptosis in Glioblastoma and Neuroblastoma: Molecular Mechanisms and Novel Therapeutic Strategies. Curr Issues Mol Biol 48, 267 (2026).

65. Bo, Y., Mu, L., Yang, Z., Li, W. & Jin, M. Research progress on ferroptosis in gliomas (Review). Oncol Lett 27, 36 (2023).

66. Biegański, M. & Szeliga, M. Disrupted glutamate homeostasis as a target for glioma therapy. Pharmacol. Rep 76, 1305–1317 (2024).

67. Biegański, M. & Szeliga, M. Disrupted glutamate homeostasis as a target for glioma therapy. Pharmacol. Rep 76, 1305–1317 (2024).

68. Doll, S. et al. Acsl4 Dictates Ferroptosis Sensitivity by Shaping Cellular Lipid Composition. Nat Chem Biol 13, 91–98 (2017).

69. Yamane, D. et al. FADS2-dependent fatty acid desaturation dictates cellular sensitivity to ferroptosis and permissiveness for hepatitis C virus replication. Cell Chem Biol 29, 799-810.e4 (2022).

70. Kloosterman, D. J. et al. Macrophage-mediated myelin recycling fuels brain cancer malignancy. Cell 187, 5336-5356.e30 (2024).

71. Scott, A. J. et al. Rewiring of cortical glucose metabolism fuels human brain cancer growth. Nature 646, 413–422 (2025).

72. Tardito, S. et al. Glutamine Synthetase activity fuels nucleotide biosynthesis and supports growth of glutamine-restricted glioblastoma. Nat Cell Biol 17, 1556–1568 (2015).

73. Mellinghoff, I. K. et al. Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial. Nat Med 29, 615–622 (2023).

74. Cloughesy, T. F. et al. Vorasidenib in IDH1-mutant or IDH2-mutant low-grade glioma (INDIGO): secondary and exploratory endpoints from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 26, 1665–1675 (2025).

75. Mellinghoff, I. K. et al. Ivosidenib in Isocitrate Dehydrogenase 1–Mutated Advanced Glioma. J Clin Oncol 38, 3398–3406 (2020).

76. Natsume, A. et al. The first-in-human phase I study of a brain-penetrant mutant IDH1 inhibitor DS-1001 in patients with recurrent or progressive IDH1-mutant gliomas. Neuro Oncol 25, 326–336 (2023).

77. Fhu, C. W. & Ali, A. Fatty Acid Synthase: An Emerging Target in Cancer. Molecules 25, 3935 (2020).

78. Kelly, W. et al. Phase II Investigation of TVB-2640 (Denifanstat) with Bevacizumab in Patients with First Relapse High-Grade Astrocytoma. Clin Cancer Res 29, 2419–2425 (2023).

79. Yasumoto, Y. et al. Inhibition of Fatty Acid Synthase Decreases Expression of Stemness Markers in Glioma Stem Cells. PLoS One 11, e0147717 (2016).

80. Seltzer, M. J. et al. Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1. Cancer Res 70, 8981–8987 (2010).

81. Han, S. et al. IDH mutation in glioma: molecular mechanisms and potential therapeutic targets. Br J Cancer 122, 1580–1589 (2020).

82. Kizilbash, S. et al. CTNI-23. PRELIMINARY SAFETY AND PHARMACOKINETICS DATA FOR A PHASE 1B TRIAL OF TELAGLENASTAT IN COMBINATION WITH RADIATION THERAPY AND TEMOZOLOMIDE IN PATIENTS WITH IDH-MUTANT GRADE 2/3 ASTROCYTOMA (NCI-10218). Neuro Oncol 24, vii75 (2022).

83. Michelakis, E. D. et al. Metabolic modulation of glioblastoma with dichloroacetate. Sci Transl Med 2, 31ra34 (2010).

84. Dunbar, E. M. et al. Phase 1 trial of dichloroacetate (DCA) in adults with recurrent malignant brain tumors. Invest New Drugs 32, 452–464 (2014).